Finally, the observation that adding CDK4/6 inhibitors to NET might stimulate anti-tumor immunity [89, 91], as has been observed with some chemotherapy agents [92, 93], suggests that patients with ER+ LABC could see improved benefit from second-line immunotherapy approaches, while avoiding cytotoxic chemotherapies. This evidence concerns the gene ESR1 and neoplasm.